Clinical trials are investigating novel immunotherapies using CAR‐T cell and antibody–drug conjugates targeting B7‐H3 for refractory/recurrent brain cancers, including glioblastoma, diffuse intrinsic pontine glioma, medulloblastoma, ependymoma, and brain metastases.37 Here, CD276 is linked to medulloblastoma.